Continuous subcutaneous insulin infusion (CSII), an alternative to multiple daily injections (MDI) in intensive insulin therapy for optimizing glycemic control in T2D, was associated with improved long-term outcomes [3,4]. The gene discussed is INS; the disease is type 2 diabetes mellitus.